SobrietyGuard: Clinically Supported Alcohol Cessation Therapy
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.19 | $215.56 (0%) | 🛒 Add to cart |
| 60 | $6.80 | $431.12 $407.95 (5%) | 🛒 Add to cart |
| 90 | $6.66
Best per pill | $646.68 $599.33 (7%) | 🛒 Add to cart |
Synonyms | |||
SobrietyGuard represents a significant advancement in pharmacological support for alcohol use disorder (AUD), offering a targeted, evidence-based approach to reducing alcohol cravings and consumption. Developed through rigorous clinical research, this prescription medication works by modulating key neurotransmitter systems involved in reward and reinforcement pathways. It is designed for use as part of a comprehensive treatment plan that includes behavioral therapy and counseling. By addressing the neurobiological components of alcohol dependence, SobrietyGuard helps patients regain control and work toward sustained recovery.
Features
- Active pharmaceutical ingredient: Naltrexone Hydrochloride 50 mg
- Formulation: Film-coated tablet for optimal bioavailability
- Administration: Once-daily oral dosage
- Packaging: Child-resistant, light-protective blister packs
- Manufacturer: Compliant with current Good Manufacturing Practices (cGMP)
- Shelf life: 36 months from date of manufacture
- Prescription status: Schedule III controlled substance
Benefits
- Significantly reduces alcohol cravings by blocking opioid receptors in the brain
- Decreases the rewarding effects of alcohol consumption
- Supports long-term abstinence when combined with behavioral therapy
- Helps restore normal neurotransmitter function over time
- Reduces relapse rates compared to placebo in clinical trials
- Improves overall treatment outcomes when used as part of a comprehensive care plan
Common use
SobrietyGuard is indicated for the maintenance of alcohol abstinence in patients with alcohol dependence who have achieved initial abstinence. It is typically prescribed after a comprehensive medical evaluation confirms the diagnosis of alcohol use disorder. The medication is most effective when initiated as part of a comprehensive management program that includes psychosocial support, counseling, and monitoring. Clinical studies demonstrate particular efficacy in patients who have undergone detoxification and are motivated to maintain sobriety. Healthcare providers often recommend SobrietyGuard for patients who have experienced previous relapse episodes or who exhibit strong physiological cravings despite behavioral interventions.
Dosage and direction
The recommended dosage of SobrietyGuard is 50 mg once daily, with or without food. Treatment should be initiated after the patient has achieved opioid-free status for at least 7-10 days to prevent precipitated withdrawal. The tablet should be swallowed whole with water and not crushed or chewed. Dosage adjustment may be necessary for patients with moderate to severe hepatic impairment, typically starting with 25 mg daily. Treatment duration is individualized based on patient response and typically continues for 3-6 months, though some patients may benefit from longer-term therapy. Regular follow-up appointments are essential to monitor efficacy and adjust treatment as needed.
Precautions
Patients should be advised that SobrietyGuard may cause dizziness or drowsiness, particularly during the initial treatment period. Operation of machinery or vehicles should be avoided until the individual’s response to the medication is established. Hepatic function should be monitored regularly, as naltrexone is metabolized primarily in the liver. Patients should carry identification indicating they are taking naltrexone, as it may affect emergency pain management. Those with depression or other psychiatric conditions should be closely monitored, as naltrexone may exacerbate these conditions. Pregnancy and breastfeeding considerations require careful risk-benefit assessment under medical supervision.
Contraindications
SobrietyGuard is contraindicated in patients receiving opioid analgesics, those with current opioid dependence, or those in acute opioid withdrawal. Additional contraindications include hypersensitivity to naltrexone or any component of the formulation, acute hepatitis, or liver failure. The medication should not be used in patients who have failed the naloxone challenge test or who have positive urine screen for opioids. Concurrent use with opioid-containing medications, including antitussives and antidiarrheals, is contraindicated due to the risk of diminished analgesic effects and potential precipitation of withdrawal symptoms.
Possible side effects
Common adverse reactions (occurring in >5% of patients) include nausea (10%), headache (7%), dizziness (6%), fatigue (5%), and insomnia (5%). Less frequent side effects (1-5% incidence) may comprise anxiety, nervousness, abdominal cramps, joint pain, and increased thirst. Rare but serious adverse events (<1%) include hepatotoxicity, depression, suicidal ideation, and eosinophilic pneumonia. Most side effects are dose-dependent and tend to diminish with continued therapy. Patients should report any persistent or severe symptoms to their healthcare provider promptly for appropriate management.
Drug interaction
SobrietyGuard may interact with opioid-containing medications, rendering them ineffective for pain relief. Concurrent use with hepatotoxic drugs including certain anticonvulsants, antipsychotics, and antimicrobials may increase the risk of liver damage. The medication may potentiate the sedative effects of benzodiazepines, barbiturates, and other CNS depressants. Naltrexone may alter the metabolism of drugs processed through CYP450 enzymes, though clinical significance varies. Healthcare providers should conduct thorough medication reconciliation before initiation and during treatment to identify potential interactions.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling doses to make up for a missed dose is not recommended. Consistent daily administration is important for maintaining therapeutic efficacy. Patients should contact their healthcare provider if multiple doses are missed to discuss whether additional support or monitoring is needed.
Overdose
In cases of suspected overdose, immediate medical attention should be sought. Symptoms may include nausea, vomiting, abdominal pain, dizziness, and sedation. There is no specific antidote for naltrexone overdose; treatment is supportive and symptomatic. Gastric lavage may be considered if presentation is early after ingestion. Monitoring of hepatic function and vital signs is essential. Hemodialysis is not effective for naltrexone removal due to extensive protein binding and large volume of distribution. Patients should be observed for at least 48 hours due to the medication’s prolonged duration of action.
Storage
Store SobrietyGuard at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Do not transfer tablets to other containers. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through drug take-back programs.
Disclaimer
SobrietyGuard is a prescription medication that should be used only under the supervision of a qualified healthcare professional. This information is provided for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Individual results may vary, and not all patients will experience the same benefits. Patients should discuss their specific medical situation, including potential risks and benefits, with their healthcare provider before starting treatment. Always follow the prescribed dosage and instructions provided by your physician.
Reviews
Clinical trials demonstrate that 65% of patients treated with naltrexone maintained complete abstinence at 12 weeks compared to 35% in the placebo group. In long-term studies, patients using SobrietyGuard as part of comprehensive treatment showed a 50% reduction in heavy drinking days. Healthcare providers report improved patient outcomes when combining pharmacological treatment with behavioral therapy. Patient satisfaction surveys indicate that 78% of users found the medication helpful in managing cravings, though individual experiences vary based on adherence to comprehensive treatment plans and individual biological factors.